Shenzhen Mingsairuilin Pharmaceutical

Shenzhen Mingsairuilin Pharmaceutical is a clinical-stage biotechnology company based in Shenzhen, China, dedicated to the discovery and development of innovative small molecule drugs for pain management and central nervous system (CNS) disorders. The company's research focus is on developing highly selective, non-opioid analgesics to provide safer alternatives for patients suffering from acute and chronic pain. Its lead candidate, MS-101, is a potent and selective Nav1.8 inhibitor currently undergoing clinical evaluation. Mingsairuilin leverages its internal R&D expertise to build a robust pipeline of candidates targeting significant unmet needs in the neurology space. The company is positioned as an emerging player in the Chinese biotech landscape, supported by regional investment and a focus on high-value therapeutic targets.